What medicine can be substituted for ensidipine?

Enasidenib is a drug that targets certain mutations in myeloproliferative disorders. It is an IDH2 inhibitor used to treat patients with IDH2 gene mutations in acute myeloid leukemia (AML). There is currently no clear alternative drug that can completely replace ensidipine in the treatment of patients with IDH2 mutations. Ifpatients are considering alternative medicines, it is recommended to consult a professional doctor or pharmacist who will be able to provide patients with the most accurate advice based on your specific situation and disease characteristics.

In primaryAML xenograft models,ensidipine also had a dose-dependent survival advantage. Ensidipine is a differentiation agent and is non-cytotoxic. Bone marrow blasts from AML patients exposed in vitro to ensidipinemutantIDH2 produce mature, functionally intact neutrophils with conserved mutant IDH2 allele frequencies, suggesting that mature cells evolved from mutant IDH2 blasts. Furthermore, no apoptosis was observed in mutant IDH2-R140 erythroleukemia (TF-1) cells treated with ensidipine for 7 days in vitro.

Encidipine research medicine is not currently on the market in China, so it cannot be included in medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic ensidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*30 tablets produced by a Laos pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to the exchange rate). Its pharmaceutical ingredients are basically the same as those of the original drugs sold abroad. For more information on overseas drug prices and specific information, please consult Yaode Medical Consultant.